Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate

INTRODUCTION: Biological disease-modifying antirheumatic drugs are particularly recommended for use in patients who are poor responders, are intolerant to conventional disease-modifying antirheumatic drugs (cDMARDs), or in whom continued treatment with cDMARDs is deemed inappropriate. We estimated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Benucci, Maurizio, Ravasio, Roberto, Damiani, Arianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525457/
https://www.ncbi.nlm.nih.gov/pubmed/28765712
http://dx.doi.org/10.2147/CEOR.S141610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525457/
https://www.ncbi.nlm.nih.gov/pubmed/28765712
http://dx.doi.org/10.2147/CEOR.S141610

Ejemplares similares